MONDAY, Dec. 17, 2018 — For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in […]
MONDAY, Dec. 17, 2018 — For treatment of human papillomavirus (HPV)-positive low-risk oropharyngeal cancer, cetuximab shows no benefit compared with the standard cisplatin regimen in […]